- Home
- KVUE vs IR Comparison
KVUE vs IR Comparison
Compare KVUE & IR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KVUE | IR |
|---|---|---|
| Founded | 2022 | 1859 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Chemicals | Industrial Machinery/Components |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.9B | 32.6B |
| IPO Year | 2023 | 2017 |
Fundamental Metrics
Financial Performance| Metric | KVUE | IR |
|---|---|---|
| Price | $17.81 | $71.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 7 |
| Target Price | $19.45 | ★ $96.00 |
| AVG Volume (30 Days) | ★ 18.3M | 3.0M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | ★ 4.82% | 0.10% |
| EPS Growth | ★ 40.74 | N/A |
| EPS | 0.48 | ★ 1.15 |
| Revenue | ★ $15,124,000,000.00 | $2,375,400,000.00 |
| Revenue This Year | $4.85 | $7.10 |
| Revenue Next Year | $2.63 | $4.78 |
| P/E Ratio | ★ $36.98 | $63.98 |
| Revenue Growth | N/A | ★ 22.48 |
| 52 Week Low | $14.02 | $68.07 |
| 52 Week High | $20.13 | $100.96 |
Technical Indicators
Market Signals| Indicator | KVUE | IR |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 28.61 |
| Support Level | $16.78 | $68.96 |
| Resistance Level | $19.15 | $72.95 |
| Average True Range (ATR) | 0.31 | 1.89 |
| MACD | -0.15 | -0.63 |
| Stochastic Oscillator | 6.61 | 3.46 |
Price Performance
Historical ComparisonAbout KVUE Kenvue Inc.
Kenvue is the world's largest pure-play consumer health company by sales, generating over $15 billion in annual revenue. Formerly known as Johnson & Johnson's consumer segment, Kenvue spun off and went public in May 2023. It operates in a variety of categories within consumer health, such as cough, cold, and allergy care, pain management, face and body care, and oral care, as well as women's health. Its portfolio has some of the most well-known brands in the space, including Tylenol, Listerine, Johnson's, Aveeno, and Neutrogena. Kenvue announced in November 2025 that it signed a deal to be fully acquired by Kimberly-Clark, with the deal expected to close during the second half of 2026.
About IR Ingersoll Rand Inc.
Ingersoll Rand was formed through the merger of Gardner Denver and Ingersoll Rand's industrial segment. The firm's portfolio consists of two business lines: industrial technologies and services, and precision and science technologies. Ingersoll Rand serves a variety of end markets, including industrial, medical, and energy. Its broad portfolio of products includes compression, blower and vacuum, and fluid management. Ingersoll Rand generated roughly $7.7 billion in revenue in 2025.